Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial

BACKGROUND—: Cangrelor is an intravenous ADP receptor antagonist that leads to potent and reversible inhibition of platelet aggregation. The relative safety and efficacy of some antiplatelet drugs in women has been disputed. METHODS AND RESULTS—: The Cangrelor versus Standard Therapy to Achieve Opti...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donoghue, Michelle L., Bhatt, Deepak L., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Prats, Jayne, Liu, Tiepu, Deliargyris, Efthymios N., Mahaffey, Kenneth W., White, Harvey D., Harrington, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894784/
https://www.ncbi.nlm.nih.gov/pubmed/26762525
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894784/
https://www.ncbi.nlm.nih.gov/pubmed/26762525
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017300

Ejemplares similares